By Lauran Neergaard

Hospital workers begin unloading precious frozen vials of COVID-19 vaccine Monday, with the first vaccinations against a scourge that has killed nearly 300,000 Americans expected later in the day.

“It feels like the cavalry is arriving,” Robert C. Garrett, CEO of Hackensack Meridian Health, said as New Jersey’s largest health network awaited delivery.

Shots made by Pfizer Inc. and its German partner BioNTech are the first authorized for emergency use by the Food and Drug Administration -- beginning what will become the largest vaccination campaign in U.S. history. Several other countries also have OK'd the vaccine, including the U.K., which started vaccinating last week.

For health care workers who, along with nursing home residents, will be first in line for vaccination, hope is tempered by grief and the sheer exhaustion of months spent battling a coronavirus that still is surging in the U.S. and around the world.

“This is mile 24 of a marathon. People are fatigued. But we also recognize that this end is in sight,” said Dr. Chris Dale of Swedish Health Services in Seattle.

Packed in dry ice to stay at ultra-frozen temperaturesthe first of nearly 3 million doses being shipped in staggered batches this week made their way by truck and by plane around the country Sunday from Pfizer’s Kalamazoo, Michigan, factory. Once they arrive at distribution centers, each state directs where the doses go next.

Some hospitals across the country spent the weekend tracking their packages, refreshing FedEx and UPS websites for clues.

More of the Pfizer-BioNTech vaccine will arrive each week. And later this week, the FDA will decide whether to green light the world’s second rigorously studied COVID-19 vaccine, made by Moderna Inc.

Now the hurdle is to rapidly get vaccine into the arms of millions, not just doctors and nurses but other at-risk health workers such as janitors and food handlers — and then deliver a second dose three weeks later.

“We’re also in the middle of a surge, and it’s the holidays, and our health care workers have been working at an extraordinary pace,” said Sue Mashni, chief pharmacy officer at Mount Sinai Health System in New York City.

Plus, the shots can cause temporary fever, fatigue and aches as they rev up people's immune systems, forcing hospitals to stagger employee vaccinations.

A wary public will be watching closely to see whether health workers embrace vaccination. Just half of Americans say they want to get vaccinated, while about a quarter don’t and the rest are unsure, according to a recent poll by The Associated Press-NORC Center for Public Health Research.

The FDA, considered the world’s most strict medical regulator, said the Pfizer-BioNTech vaccine appears safe and strongly protective -- and laid out the data behind it in a daylong public meeting last week for scientists and consumers alike to see.

“Please people, when you look back in a year and you say to yourself, ‘Did I do the right thing?’ I hope you’ll be able to say, ‘Yes, because I looked at the evidence,’” Dr. Francis Collins, director of the National Institutes of Health, said Sunday on NBC’s Meet the Press. “People are dying right now. How could you possibly say, ‘Let’s wait and see.’”

Still, emergency use means the vaccine was cleared for widespread use before a final study in nearly 44,000 people is complete -- and that research is continuing to try to answer additional questions. While effective against COVID-19 illness, it’s not yet clear if vaccination will stop the symptomless spread that accounts for half of all cases.

The shots still must be studied in children, and during pregnancy. But the American College of Obstetricians and Gynecologists said late Sunday that vaccination should not be withheld from pregnant women who otherwise would qualify.

While the vaccine was determined to be safe, regulators in the U.K. are investigating several severe allergic reactions. The FDA’s instructions tell providers not to give it to those with a known history of severe allergic reactions to any of its ingredients.

AP journalists Tamara Lush and Kathy Young contributed to this report.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
New BA.2 Variant Predicted to Boost Covid Cases in U.S.
A subvariant of the omicron COVID-19 variant called BA.2 is causing an outbreak overseas. Now, some health experts worry it could also lead to an increase in COVID-19 cases in the U.S. Dr. Amesh Adalja, infectious disease specialist and senior scholar at Johns Hopkins Center for Health Security, joins Cheddar News to discuss.
Green Battery Materials Maker Nouveau Monde Graphite Aims to Power Energy Revolution
Nouveau Monde Graphite says it wants to power the sustainable energy revolution. The Canadian company is developing carbon-neutral battery materials to serve the growing EV and cleantech markets and is doing so via a mining and manufacturing operation in Quebec. Eric Desaulniers, founder, president & CEO of Nouveau Monde Graphite, joins Cheddar News' Closing Bell to discuss.
There's A New Subvariant. How Concerned Should We Be?
Health experts are warning an even more contagious subvariant of Omicron, known as BA.2, could soon lead to another surge in Covid cases here in the U.S. The variant has already driven cases to skyrocket in China and Europe, which has historically served as a preview to the pattern the U.S. has seen throughout the pandemic. This comes at a time when protection from booster shots is waning for most people who got them. Dr. Jen Caudle, Family Physician & Associate Professor at Rowan University, explains what we can do to protect ourselves against the new variant and how we should act as warnings of another surge rise.
Cresco Labs to Become the Largest U.S. Cannabis Company by Sales With Columbia Care Acquisition
Cannabis producer Cresco Labs is acquiring rival Columbia Care in a $2 billion all-stock deal, creating the largest U.S. cannabis company by sales. The deal, which is expected to close in the fourth quarter of 2022, is one of the biggest in the industry's history and would make Cresco the dominant player in a market projected to reach $46 billion in revenue by 2026. Charlie Bachtell, CEO of Cresco Labs, joins Cheddar News' Closing Bell to discuss.
Breaking Down Moderna Seeking COVID Vaccine Approval for Kids Under 6
Moderna announced it's seeking emergency use approval for its COVID-19 vaccine from the FDA for children under 6 years old. A former FDA associate commissioner and the president and co-founder of the Center for Medicine in the Public Interest (CMPI) Peter Pitts joined Cheddar News to talk about the timeline, benefits, and risks that come with the approval of the vaccine. "We want to protect their parents and their grandparents and their caregivers and their daycare providers, so it's all about protecting not just the kids but all around the people that are surrounding those kids," he said.
Load More